<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3763">
  <stage>Registered</stage>
  <submitdate>17/12/2012</submitdate>
  <approvaldate>17/12/2012</approvaldate>
  <nctid>NCT01757184</nctid>
  <trial_identification>
    <studytitle>A Multicenter Study of SBC-102 (Sebelipase Alfa) in Patients With Lysosomal Acid Lipase Deficiency/ ARISE (Acid Lipase Replacement Investigating Safety and Efficacy)</studytitle>
    <scientifictitle>A Multicenter, Randomized, Placebo-Controlled Study of SBC-102 in Patients With Lysosomal Acid Lipase Deficiency</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>LAL-CL02</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cholesterol Ester Storage Disease (CESD)</healthcondition>
    <healthcondition>Lysosomal Acid Lipase Deficiency</healthcondition>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - SBC-102 [sebelipase alfa] (1 mg/kg)
Treatment: drugs - Placebo

Experimental: SBC-102 [sebelipase alfa] - Every other week IV infusions of SBC-102

Placebo Comparator: Placebo - Every other week infusions of placebo


Treatment: drugs: SBC-102 [sebelipase alfa] (1 mg/kg)


Treatment: drugs: Placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of Subjects Achieving Alanine Aminotransferase (ALT) Normalization - The primary efficacy endpoint was the percentage of subjects who achieve alanine aminotransferase (ALT) normalization (i.e., ALT below the age- and gender-specific upper limit of normal provided by the central laboratory performing the assay) at the end of the double-blind treatment period (i.e., the last double-blind assessment), relative to placebo.</outcome>
      <timepoint>Baseline to the end of the double-blind period (week 20)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage Change From Baseline in LDL-c - Relative reduction (percentage change from baseline) in LDL-c at the end of the double-blind period.</outcome>
      <timepoint>Baseline to the end of the double-blind period (week 20)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage Change From Baseline in Non-HDL-c - Relative reduction (percentage change from baseline) in non-high density lipoprotein cholesterol (non-HDL-c) at the end of the double-blind period</outcome>
      <timepoint>Baseline to the end of the double-blind period (week 20)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Subjects Achieving Aspartate Aminotransferase (AST) Normalization - The percentage of subjects with an abnormal baseline aspartate aminotransferase (AST; i.e., &gt;ULN) who achieved AST normalization, based on age- and gender-specific normal ranges provided by the central laboratory performing the assay.</outcome>
      <timepoint>Baseline to the end of the double-blind period (week 20)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage Change From Baseline in Triglycerides - Relative reduction (percentage change from baseline) in triglycerides at the end of the double-blind period</outcome>
      <timepoint>Baseline to the end of the double-blind period (week 20)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage Change From Baseline in HDL-c - Relative increase (percentage change from baseline) in high density lipoprotein cholesterol (HDL-c) at the end of the double-blind period</outcome>
      <timepoint>Baseline to the end of the double-blind period (week 20)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage Change From Baseline in Liver Fat Content - Decrease in liver fat content, as assessed by magnetic resonance imaging (MRI), in the subset of subjects for whom imaging was performed</outcome>
      <timepoint>Baseline to the end of the double-blind period (week 20)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Subjects With Improvement in Liver Histology (Decrease of &gt;5% in Hepatic Steatosis Score) - The number of subjects who had an improvement in hepatic histology (i.e., a decrease of &gt;5% in hepatic steatosis score) from baseline to Week 20, as determined by blinded central review, in the subset of subjects for whom liver biopsy was performed.</outcome>
      <timepoint>Baseline to the end of the double-blind period (week 20)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage Change From Baseline in Liver Volume - Relative reduction (percentage change from baseline) in liver volume, as assessed by magnetic resonance imaging, in the subset of subjects for whom imaging was performed</outcome>
      <timepoint>Baseline to the end of the double-blind period (week 20)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subject and/or subject's parent or legal guardian provides informed consent

          -  Subject is =4 years of age

          -  Deficiency of LAL enzyme activity confirmed by dried blood spot (DBS) testing at
             screening

          -  ALT =1.5x ULN

          -  Female subjects of childbearing potential must not be pregnant or breastfeeding

          -  Subjects receiving lipid-lowering therapies must be on a stable dose of the medication

          -  Subjects receiving medications for the treatment of non-alcoholic fatty liver disease
             must be on a stable dose</inclusivecriteria>
    <inclusiveminage>4</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Severe hepatic dysfunction (Child-Pugh Class C)

          -  Other medical conditions or comorbidities which, in the opinion of the Investigator,
             would interfere with study compliance or data interpretation

          -  Previous hematopoietic or liver transplant procedure

          -  Received treatment with high-dose corticosteroids (acute or chronic) within 26 weeks.
             (Note: Subjects receiving maintenance therapy with low-dose oral, intranasal, topical,
             or inhaled corticosteroids are considered eligible for the study)

          -  Known hypersensitivity to eggs

          -  Participated in a study employing an investigational medicinal product within 4 weeks
             prior to randomization</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>66</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/01/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital> - Parkville</hospital>
    <hospital> - Brisbane</hospital>
    <hospital> - Newcastle</hospital>
    <hospital> - Perth</hospital>
    <postcode> - Parkville</postcode>
    <postcode> - Brisbane</postcode>
    <postcode> - Newcastle</postcode>
    <postcode> - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Delaware</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Córdoba Province</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio Grande do Sul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>São Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state>Zagreb</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Olomouc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Prague</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 15</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre les Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bergamo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Genoa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Padova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Turin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tottori</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Albacete</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Elche</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Oviedo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Ankara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Plymouth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Salford</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Alexion Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This Phase 3 study will evaluate the efficacy and safety of 1 mg/kg IV infusions of SBC-102
      (sebelipase alfa) administered every other week in patients with late onset lysosomal acid
      lipase (LAL) deficiency (cholesteryl ester storage disease).

      Late onset LAL Deficiency is an underappreciated cause of cirrhosis, liver failure and
      dyslipidemia. There is currently no standard treatment for LAL Deficiency other than
      supportive care. Enzyme replacement therapy (ERT) may be a potential new treatment option for
      LAL Deficiency patients.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01757184</trialwebsite>
    <publication>Balwani M, Breen C, Enns GM, Deegan PB, Honzík T, Jones S, Kane JP, Malinova V, Sharma R, Stock EO, Valayannopoulos V, Wraith JE, Burg J, Eckert S, Schneider E, Quinn AG. Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease. Hepatology. 2013 Sep;58(3):950-7. doi: 10.1002/hep.26289. Epub 2013 Mar 28.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>